Parsey Merdad

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
14
Insider Sells Sum
$22.24M

Insider Activity of Parsey Merdad

According to the SEC Form 4 filings, Parsey Merdad, being in a position of

  1. Chief Medical Officer at Gilead Sciences, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 227277 shares for $20.43M,
    over all time since 2020-08-17, has bought 0 shares, and sold 250108 shares for $22.24M.

The largest sale of all time was on 2024-11-27 and amounted to 164211 share of Gilead Sciences, Inc. for $15.09M.

Biography of Parsey Merdad

No biography is available at this moment.

2024-11-27SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
164,211
0.0131%
$91.92$15.09M-0.03%
2024-11-06SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
25,590
0.0021%
$91.50$2.34M+0.75%
2024-10-01SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
2,000
0.0002%
$83.83$167,660+7.8%
2024-09-12SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
21,246
0.0017%
$84.50$1.8M+7.8%
2024-07-01SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
2,000
0.0002%
$68.63$137,2600%
2024-04-01SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
2,000
0.0002%
$72.96$145,920+4.55%
2024-02-29SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
8,230
0.0007%
$72.74$598,624+2.96%
2024-02-28SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
2,000
0.0002%
$73.18$146,360+2.06%
2023-09-12SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
1,501
0.0001%
$76.99$115,562-2.57%
2023-06-13SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
1,485
0.0001%
$76.90$114,197-2.34%
2023-03-13SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
6,126
0.0005%
$78.99$483,893-0.46%
2023-03-01SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
12,984
0.001%
$79.96$1.04M-0.4%
2022-12-30SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
553
<0.0001%
$85.33$47,187-7.23%
2020-08-17SaleGilead Sciences, Inc.
GILD
Chief Medical Officer
182
<0.0001%
$68.32$12,434-3.81%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.